New Drug Application submitted to FDA for pralsetinib for treatment of advanced RET mutant and RET fusion-positive thyroid cancers

Pralsetinib is an investigational once-daily precision therapy designed to potently and selectively inhibit RET fusions and mutations, which are key disease drivers in many cancer types, including non-small cell lung cancer and medullary thyroid cancer.


Biospace Inc.